Published in AIDS Behav on May 01, 2014
An interdisciplinary framework for measuring and supporting adherence in HIV prevention trials of ARV-based vaginal rings. J Int AIDS Soc (2014) 0.90
Development of a composite measure of product adherence, protocol compliance, and semen exposure using DNA and protein biomarkers for topical HIV prevention studies. PLoS One (2014) 0.75
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19
A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med (2001) 9.98
Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management. AIDS Behav (2006) 8.11
Methodological challenges in research on sexual risk behavior: II. Accuracy of self-reports. Ann Behav Med (2003) 6.67
Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr (2006) 3.93
Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav (2010) 3.08
Designing a mobile phone-based intervention to promote adherence to antiretroviral therapy in South India. AIDS Behav (2010) 2.30
NIMH/APPC workgroup on behavioral and biological outcomes in HIV/STD prevention studies: a position statement. Sex Transm Dis (2000) 2.05
A mixed methods and triangulation model for increasing the accuracy of adherence and sexual behaviour data: the Microbicides Development Programme. PLoS One (2010) 1.97
Health technologies for monitoring and managing diabetes: a systematic review. J Diabetes Sci Technol (2009) 1.70
Adherence and its measurement in phase 2/3 microbicide trials. AIDS Behav (2010) 1.60
Evaluation of an electronic device for real-time measurement of alcohol-based hand rub use. Infect Control Hosp Epidemiol (2009) 1.58
Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizers. Chest (2011) 1.38
An interdisciplinary HIV-adherence program combining motivational interviewing and electronic antiretroviral drug monitoring. AIDS Care (2011) 1.06
A persuasive toothbrush to enhance oral hygiene adherence. AMIA Annu Symp Proc (2008) 0.97
Measuring adherence to antiretroviral therapy in northern Tanzania: feasibility and acceptability of the Medication Event Monitoring System. BMC Public Health (2011) 0.93
Feasibility, performance, and acceptability of the Wisebag™ for potential monitoring of daily gel applicator use in Durban, South Africa. AIDS Behav (2013) 0.91
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19
Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med (2010) 10.90
Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med (2011) 5.31
The impact of migration on HIV-1 transmission in South Africa: a study of migrant and nonmigrant men and their partners. Sex Transm Dis (2003) 5.09
The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol (2011) 4.18
Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection. N Engl J Med (2015) 3.64
Health in South Africa: changes and challenges since 2009. Lancet (2012) 3.44
Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. PLoS One (2008) 3.40
Achieving the health Millennium Development Goals for South Africa: challenges and priorities. Lancet (2009) 3.35
HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet (2006) 2.86
Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog (2009) 2.70
Stabilizing HIV prevalence masks high HIV incidence rates amongst rural and urban women in KwaZulu-Natal, South Africa. Int J Epidemiol (2010) 2.53
Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med (2012) 2.48
Invited commentary: condom effectiveness-will prostate-specific antigen shed new light on this perplexing problem? Am J Epidemiol (2003) 2.45
Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa. J Infect Dis (2012) 2.42
Microbicides & their implications in HIV prevention. Indian J Med Res (2010) 2.36
The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J Virol (2007) 2.29
Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J Virol (2011) 2.26
The female condom: is "just as good" good enough? Sex Transm Dis (2003) 2.12
The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial. J Womens Health (Larchmt) (2003) 2.03
Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav (2013) 2.03
Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. PLoS One (2011) 1.99
Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J Virol (2009) 1.78
Global development. Family planning and the Millennium Development Goals. Science (2010) 1.78
Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. J Infect Dis (2012) 1.73
Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog (2013) 1.65
The changing epidemiology of HIV in 2013. Curr Opin HIV AIDS (2013) 1.31
Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa. J Acquir Immune Defic Syndr (2011) 1.31
Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. J Acquir Immune Defic Syndr (2003) 1.30
Determinants of prevalent HIV infection and late HIV diagnosis among young women with two or more sexual partners in Beira, Mozambique. PLoS One (2013) 1.27
HIV incidence in young girls in KwaZulu-Natal, South Africa--public health imperative for their inclusion in HIV biomedical intervention trials. AIDS Behav (2012) 1.26
Utility of tuberculosis directly observed therapy programs as sites for access to and provision of antiretroviral therapy in resource-limited countries. Clin Infect Dis (2004) 1.18
Genital tract inflammation during early HIV-1 infection predicts higher plasma viral load set point in women. J Infect Dis (2012) 1.17
Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials (2011) 1.15
Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies. J Virol (2013) 1.13
Ratio of monocytes to lymphocytes in peripheral blood identifies adults at risk of incident tuberculosis among HIV-infected adults initiating antiretroviral therapy. J Infect Dis (2013) 1.12
The future role of rectal and vaginal microbicides to prevent HIV infection in heterosexual populations: implications for product development and prevention. Sex Transm Infect (2011) 1.10
Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 trial. AIDS Behav (2014) 1.09
APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4+ T-cell counts and plasma viral load. AIDS (2010) 1.08
Field study of adult male circumcision using the ShangRing in routine clinical settings in Kenya and Zambia. J Acquir Immune Defic Syndr (2014) 1.07
Global epidemiology of HIV-AIDS. Infect Dis Clin North Am (2007) 1.06
Adherence in the CAPRISA 004 tenofovir gel microbicide trial. AIDS Behav (2014) 1.06
HIV prevalence among high school learners - opportunities for schools-based HIV testing programmes and sexual reproductive health services. BMC Public Health (2012) 1.04
Modeling the impact of a partially effective HIV vaccine on HIV infection and death among women and infants in South Africa. J Acquir Immune Defic Syndr (2006) 1.03
Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection. Int J Clin Pharm (2013) 1.02
Interventions to modify sexual risk behaviours for preventing HIV in homeless youth. Cochrane Database Syst Rev (2011) 0.98
The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. Eur J Clin Pharmacol (2011) 0.98
Association of polymorphisms in the LEDGF/p75 gene (PSIP1) with susceptibility to HIV-1 infection and disease progression. AIDS (2011) 0.97
Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial. J Acquir Immune Defic Syndr (2012) 0.97
Natural killer cell function in women at high risk for HIV acquisition: insights from a microbicide trial. AIDS (2012) 0.96
Anaemia in acute HIV-1 subtype C infection. PLoS One (2008) 0.96
Bacterial vaginosis and the risk of trichomonas vaginalis acquisition among HIV-1-negative women. Sex Transm Dis (2014) 0.96
Diagnostic Accuracy of the Point-of-Care Xpert HIV-1 Viral Load Assay in a South African HIV Clinic. J Acquir Immune Defic Syndr (2016) 0.96
When to start antiretroviral therapy during tuberculosis treatment? Curr Opin Infect Dis (2013) 0.94
Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial. Antivir Ther (2012) 0.94
Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness. J Acquir Immune Defic Syndr (2015) 0.93
Results of effectiveness trials of PRO 2000 gel: lessons for future microbicide trials. Future Microbiol (2010) 0.93
Differential impact of magnitude, polyfunctional capacity, and specificity of HIV-specific CD8+ T cell responses on HIV set point. J Virol (2013) 0.92
Mucosal Escherichia coli bactericidal activity and immune mediators are associated with HIV-1 seroconversion in women participating in the HPTN 035 trial. J Infect Dis (2012) 0.92
Feasibility, performance, and acceptability of the Wisebag™ for potential monitoring of daily gel applicator use in Durban, South Africa. AIDS Behav (2013) 0.91
Partner age difference and prevalence of chlamydial infection among young adult women. Sex Transm Dis (2008) 0.91
Antiretroviral therapy: challenges and options in South Africa. Lancet (2003) 0.91
Incidence of Sexually Transmitted Infections among HIV-positive sex workers in KwaZulu-Natal, South Africa. Sex Transm Dis (2002) 0.89
Screening young adults for prevalent chlamydial infection in community settings. Ann Epidemiol (2008) 0.89
Randomised controlled trial of alternative male and female condom promotion strategies targeting sex workers in Madagascar. Sex Transm Infect (2007) 0.89
Y chromosome and HIV DNA detection in vaginal swabs as biomarkers of semen and HIV exposure in women. Sex Transm Dis (2014) 0.88
Limited HIV-1 superinfection in seroconverters from the CAPRISA 004 Microbicide Trial. J Clin Microbiol (2013) 0.87
Treatment of maternal syphilis in rural South Africa: effect of multiple doses of benzathine penicillin on pregnancy loss. Trop Med Int Health (2004) 0.87
The preventive misconception: experiences from CAPRISA 004. AIDS Behav (2014) 0.86
Risk Factors for HIV Acquisition in High Risk Women in a Generalised Epidemic Setting. AIDS Behav (2015) 0.85
An AIDS-free generation? Science (2012) 0.85
The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis. S Afr Med J (2010) 0.85
Trends in HIV Prevalence in Pregnant Women in Rural South Africa. J Acquir Immune Defic Syndr (2015) 0.84
Experience in international clinical research: the HIV Prevention Trials Network. Clin Investig (Lond) (2011) 0.84
Neither microbial translocation nor TLR responsiveness are likely explanations for preexisting immune activation in women who subsequently acquired HIV in CAPRISA 004. J Acquir Immune Defic Syndr (2013) 0.83
A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection. Expert Opin Investig Drugs (2012) 0.82
Health-related quality of life dynamics of HIV-positive South African women up to ART initiation: evidence from the CAPRISA 002 acute infection cohort study. AIDS Behav (2014) 0.82